Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning of the coronavirus pandemic through the middle of last June, shares of NovoNordisk delivered more than a five-fold return.

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was over. It said the Danish pharmaceutical had sufficient supply of its semaglutide therapies to meet current and future,

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. Novo Nordisk stock is up around 75% despite a pullback in recent months.

Bernstein analysts told investors in a note Tuesday that Eli Lilly (NYSE:LLY) is gaining ground in the GLP-1 market, edging closer to market share parity with Novo Nordisk (NYSE:NVO).

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom in the fourth quarter of last year,

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO stock a buy.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug.

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why now might be the time to invest.

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. | The company is adding higher-dose Zepbound options to its online pharmacy and trimming costs for its lower-dose options by $50.